Phase II study of paclitaxel and irinotecan chemotherapy in patients with advanced nonsmall cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 4, 2007, Pages 358-360

  Oshita, Fumihiro ^a   Saito, Haruhiro ^a   Yamada, Kouzo ^a   Noda, Kazumasa ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

Irinotecan; Lung cancer; Nonsmall cell; Paclitaxel

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; PACLITAXEL; RANITIDINE; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34548379496     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000258091.25459.d1     Document Type: Article

References (11)

1. American Society of Clinical Oncology. Treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330-353.
2. D'Addario G, Pintile M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23:2926-2936.
3. Negoro S, Masuda N, Takada Y, et al. Randomized phase III trial of irinotecan combined with cisplatin for advanced non-small cell lung cancer. Br J Cancer. 2003;88:335-341.
4. Fukuda M, Nishio K, Shiraishi J, et al. Effects of combinations of CPT-11, paclitaxel and other anticancer agents on human small cell lung cancer cells. Cell Pharmacol. 1996;3:1-6.
5. Yamada K, Ikehara M, Tanaka G, et al. Dose escalation study of paclitaxel in combination with fixed dose irinotecan in patients with advanced non-small cell lung cancer (JCOG9807). Oncology. 2004;66:94-100.
6. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
7. NCI-CTC, version 3, National Cancer Institute: Common Toxicity Criteria, version 2. http://ctep.cancer.gov/reporting/CTC-3.html.
8. Simon R. Optimal two-stage designs for phase II clinical trial. Control Clin Trial. 1989;10:1-10.
9. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
10. Yamamoto N, Negoro S, Chikazawa H, et al. Pharmacokinetic interaction of the combination of paclitaxel and irinotecan in vivo and clinical study [Abstract]. Proc Am Soc Clin Oncol. 1999;18:187.
11. Komuro Y, Udagawa Y, Susumu N, et al. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin. Jpn J Cancer Res. 2001;92:1242-1250.